Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Non-Current Deffered Revenue for 6 consecutive years, with $31.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $31.8 million; the trailing twelve-month figure through Jun 2026 stood at $31.8 million (changed 0.0% YoY), and the FY2025 full-year result was $31.8 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $31.8 million in Q2 2026 per KNSA's latest filing, from $31.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $31.8 million in Q4 2024 and bottomed at $11.8 million in Q2 2024.
• Historically, Non-Current Deffered Revenue has averaged $19.8 million across 5 years, with a median of $12.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deffered Revenue decreased 16.38% in 2023, then jumped 169.61% in 2025.
• Over 5 years, Non-Current Deffered Revenue stood at $12.0 million in 2022, then fell by 0.38% to $12.0 million in 2023, then surged by 166.11% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025, then changed by 0.0% to $31.8 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $31.8 million, $31.8 million, and $31.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.